Response: Intrathecal methotrexate and central nervous system events

Blood

Volumn 114, Issue 9, 2009, Pages 1999-2000

  Schmitz, Norbert ^a   Zeynalova, Samira ^b   Loeffler, Markus ^b   Pfreundschuh, Michael ^c  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LARGE CELL LYMPHOMA; LETTER; LEUKOPENIA; MEDICAL INFORMATION; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; IMMUNOTHERAPY; INTRASPINAL DRUG ADMINISTRATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RISK; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM DISEASES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOTHERAPY; INJECTIONS, SPINAL; LYMPHOMA, LARGE-CELL, ANAPLASTIC; METHOTREXATE; PREDNISONE; PROGNOSIS; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; VINCRISTINE;

EID: 70349250190     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-226076     Document Type: Letter

References (1)

1. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897-903.